Literature DB >> 9083477

Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.

J Hultén1, N M Bonham, U Nillroth, T Hansson, G Zuccarello, A Bouzide, J Aqvist, B Classon, U H Danielson, A Karlén, I Kvarnström, B Samuelsson, A Hallberg.   

Abstract

Ten C2-symmetric cyclic urea and sulfamide derivatives have been synthesized from L-mannonic gamma-lactone and D-mannitol. The results of experimental measurement of their inhibitory potencies against HIV-1 protease were compared to calculated free energies of binding derived from molecular dynamics (MD) simulations. The compounds were selected, firstly, to enable elucidation of the role of stereochemistry for binding affinity (1a-d) and, secondly, to allow evaluation of the effects of variation in the link to the P1 and P1' phenyl groups on affinity (1a and 2-5). Thirdly, compounds with hydrogen bond-accepting or-donating groups attached to the phenyl groups in the P2 and P2' side chains (6 and 7) were selected. Binding free energies were estimated by a linear response method, whose predictive power for estimating binding affinities from MD simulations was demonstrated.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9083477     DOI: 10.1021/jm960728j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Inhibition and substrate recognition--a computational approach applied to HIV protease.

Authors:  H M Vinkers; M R de Jonge; E D Daeyaert; J Heeres; L M H Koymans; J H van Lenthe; P J Lewi; H Timmerman; P A J Janssen
Journal:  J Comput Aided Mol Des       Date:  2003-09       Impact factor: 3.686

2.  Protein-ligand binding free energy estimation using molecular mechanics and continuum electrostatics. Application to HIV-1 protease inhibitors.

Authors:  V Zoete; O Michielin; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2003-12       Impact factor: 3.686

3.  Processing multimode binding situations in simulation-based prediction of ligand-macromolecule affinities.

Authors:  Akash Khandelwal; Viera Lukacova; Daniel M Kroll; Soumyendu Raha; Dogan Comez; Stefan Balaz
Journal:  J Phys Chem A       Date:  2005-07-28       Impact factor: 2.781

Review 4.  Identification of HIV inhibitors guided by free energy perturbation calculations.

Authors:  Orlando Acevedo; Zandrea Ambrose; Patrick T Flaherty; Hadega Aamer; Prashi Jain; Somisetti V Sambasivarao
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Computation of affinity and selectivity: binding of 2,4-diaminopteridine and 2,4-diaminoquinazoline inhibitors to dihydrofolate reductases.

Authors:  J Marelius; M Graffner-Nordberg; T Hansson; A Hallberg; J Aqvist
Journal:  J Comput Aided Mol Des       Date:  1998-03       Impact factor: 3.686

6.  Ligand binding affinity prediction by linear interaction energy methods.

Authors:  T Hansson; J Marelius; J Aqvist
Journal:  J Comput Aided Mol Des       Date:  1998-01       Impact factor: 3.686

7.  Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.

Authors:  U Nillroth; L Vrang; P O Markgren; J Hultén; A Hallberg; U H Danielson
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Computational analysis of binding of P1 variants to trypsin.

Authors:  B O Brandsdal; J Aqvist; A O Smalås
Journal:  Protein Sci       Date:  2001-08       Impact factor: 6.725

9.  Synthesis, characterization and biological evaluation of some novel P-heterocyclic androst-4-ene derivatives.

Authors:  Natalija M Krstić; Vladimir D Pavlović; Irena T Novaković; Ivana Z Matić; Dušan M Sladić
Journal:  Mol Divers       Date:  2013-06-09       Impact factor: 2.943

10.  Investigation on the Anticancer Activity of Symmetric and Unsymmetric Cyclic Sulfamides.

Authors:  Jaden Jungho Jun; Divya Duscharla; Ramesh Ummanni; Paul R Hanson; Sanjay V Malhotra
Journal:  ACS Med Chem Lett       Date:  2021-01-15       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.